SCHEMBL2575692

SCHEMBL2575692

CNc1nonc1-c1nc2ccccc2n1CC(=O)c1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.58
GUSB P08236 1/20 0.58
CXCR3 P49682 1/20 0.56
KDM4E B2RXH2 8/20 0.55
ALDH1A1 P00352 8/20 0.55
HTT P42858 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HPGD P15428 4/20 0.55
MAPT P10636 4/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
TSHR P16473 5/20 0.53
HSD17B10 Q99714 4/20 0.53
MAPK1 P28482 2/20 0.53
NPSR1 Q6W5P4 2/20 0.52
USP2 O75604 2/20 0.52
TP53 P04637 2/20 0.51
BCHE P06276 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2581454 0.90 KDM4E (0.69) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL2582149 0.86 TSHR (0.57) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL2578815 0.85 CTSD (0.51) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL1385523 0.85 KDM4E (0.71) CTSDGUSBKDM4EALDH1A1HTT
SCHEMBL1384956 0.84 ALDH1A1 (0.56) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL2583244 0.84 CTSD (0.58) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL5037413 0.81 KDM4E (0.62) KDM4EALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL11302849 0.80 ALDH1A1 (0.51) CTSDGUSBCXCR3KDM4EALDH1A1
SCHEMBL23118938 0.80 KDM4E (0.53) KDM4EALDH1A1HTTSMN1; SMN2HPGD
SCHEMBL17826523 0.78 ALDH1A1 (0.55) KDM4EALDH1A1HTTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE42890-E1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2011-11-01 US disclosed
US-7385061-B2 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases BASILEA PHARMACEUTICA AG (CH) 2008-06-10 US disclosed
EP-1636215-B1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2008-01-23 EP disclosed
US-20070043061-A1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043061-A1 Furazanobenzimidazoles FOXO1, CYP2F1, OXER1 CTSD 4618/4885GUSB 4632/4885CXCR3 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.